| Theme |
Dialysis Amyloidosis -- Present State of the Art |
| Title |
Efficacy of renal transplantation for hemodialysis-related amyloidosis |
| Author |
Kunio Morozumi |
Department of Internal Medicine, Nagoya Daini Red Cross Hospital |
| Author |
Asami Takeda |
Department of Internal Medicine, Nagoya Daini Red Cross Hospital |
| Author |
Atsuhiro Yoshida |
Division of Nephrology, Nagoya City University |
| Author |
Toshihito Haba |
Department of Surgery, Nagoya Daini Red Cross Hospital |
| Author |
Yoshihiro Tominaga |
Department of Surgery, Nagoya Daini Red Cross Hospital |
| Author |
Kazuharu Uchida |
Department of Surgery, Nagoya Daini Red Cross Hospital |
| Author |
Hiroshi Takagi |
JR Tokai General Hospital |
| [ Summary ] |
Dialysis-related amyloidosis (DRA) is a disorder that commonly develops in long-term dialysis patients. No successful treatment by any blood purification has been confirmed. Successful renal transplantation is considered to be the only effective treatment for DRA. Successful renal transplantation reduces plasma beta-2-microglobulin levels to normal and joint pains are usually eliminated quickly. Renal transplantation within the first 10 years of end-stage renal failure can prevent the development of DRA. Our data revealed the prophylactic effects of renal transplantation on the development of DRA. Both bones and synovium lesions related to DRA are less prominent in renal transplantation groups with long-term end-stage renal failure of over a 10 year period. There may also be some regression in amyloid deposits. In comparison, bonecysts resolve much more slowly. |